Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases.
In: PR Newswire, 2022-05-15
Zeitungsartikel
Zugriff:
Titel: |
Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases.
|
---|---|
Zeitschrift: | PR Newswire, 2022-05-15 |
Veröffentlichung: | 2022 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|